Drug Profile
AR 324
Latest Information Update: 17 Apr 1997
Price :
$50
*
At a glance
- Originator Antigenics
- Class Antineoplastics
- Mechanism of Action Tumour necrosis factor stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 17 Apr 1997 Discontinued-Preclinical for Cancer in USA (Unknown route)
- 01 Feb 1995 Preclinical development for Cancer in USA (Unknown route)